Very strong new study on MANF in age related diabetes

New Post Public Reply Private Reply Replies (0) Message Board
freegriff
387
Very strong new study on MANF in age related diabetes Identification and validation of the pivotal role of MANF gene in pancreatic β-cell aging using bioinformatics
Jiang Liu et al. Biochem Biophys Rep. 2025

Biochem Biophys Rep. 2025 Jul 8:43:102106.
doi: 10.1016/j.bbrep.2025.102106. eCollection 2025 Sep.

Abstract
Pancreatic β-cells are essential for maintaining endocrine function, and their age-related decline is strongly associated with insulin resistance and an increased risk of developing diabetes. By integrating cross-species bioinformatics analyses (single-cell RNA-seq data from young and aged cynomolgus macaques and microarray data from young and old mouse pancreatic β-cells), we identified mesencephalic astrocyte-derived neurotrophic factor (MANF), an endoplasmic reticulum (ER) stress-related gene, as a key regulator of β-cell aging. Using a d-galactose (D-gal)-induced aging mouse model (400 mg/kg/day for 10 weeks) and H2O2 (300 μM)-treated MIN6 cells, we demonstrated that MANF expression was downregulated in the aging models, which also exhibited elevated levels of cyclin-dependent kinase inhibitor P21, insulin resistance, impaired glucose tolerance, and decreased insulin secretion. Notably, administration of human recombinant MANF (hrMANF) (0.7 mg/kg, three times/week) reversed the insulin resistance, improved glucose tolerance and insulin secretion. Our study is the first to establish MANF as a guardian of β-cell proteostasis during aging, thus offering a novel therapeutic avenue for diabetes by targeting β-cell senescence. It's a finding with high clinical relevance for aging populations, as it directly addresses the critical reasons for age-related diabetes progression and provides a strategy to preserve β-cell function and reverse aging-related diabetes in older adults.

https://pubmed.ncbi.nlm.nih.gov/40688493/

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials